Latest Trials Latest NewsFAQ

BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Biological: Nivolumab
Drug: Prednisone
Other: Placebo
Drug: Docetaxel

First Posted Date: 2019-09-23

Last Posted Date: 2024-07-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1030

Registration Number: NCT04100018

Locations: 🇺🇸
Local Institution - 0011, San Antonio, Texas, United States
🇺🇸
Local Institution - 0081, Santa Monica, California, United States
🇺🇸
Local Institution - 0055, Rancho Mirage, California, United States

and more 290 locations

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma

Phase 3

Active, not recruiting

Conditions: Melanoma

Interventions: Other: Placebo
Biological: Nivolumab

First Posted Date: 2019-09-23

Last Posted Date: 2023-11-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 790

Registration Number: NCT04099251

Locations: 🇺🇸
Local Institution - 0135, Baltimore, Maryland, United States
🇺🇸
Local Institution - 0078, Boston, Massachusetts, United States
🇨🇦
Local Institution - 0124, Kingston, Ontario, Canada

and more 126 locations

A Study of Dasatinib Management Among CP-CML (Chronic Phase, Chronic Myeloid Leukemia) Participants Initiating Dasatinib in a Real Life Setting

Completed

Conditions: Chronic Myeloid Leukemia

Interventions: Other: Non-Interventional

First Posted Date: 2019-09-13

Last Posted Date: 2022-06-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 177

Registration Number: NCT04089839

Locations: 🇫🇷
Local Institution, Paris, France

A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma

Phase 2

Terminated

Conditions: Renal Cell Carcinoma

Interventions: Biological: Nivolumab
Biological: Ipilimumab

First Posted Date: 2019-09-12

Last Posted Date: 2023-01-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 5

Registration Number: NCT04088500

Locations: 🇺🇸
Washington University School of Medicine in St. Louis WUSTL, Saint Louis, Missouri, United States
🇨🇦
Local Institution, Quebec City, Quebec, Canada
🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

and more 6 locations

An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition.

Phase 1

Completed

Conditions: Healthy Male Volunteers

Interventions: Drug: BMS-986165
Drug: Pyrimethamine

First Posted Date: 2019-09-12

Last Posted Date: 2020-08-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 16

Registration Number: NCT04086719

Locations: 🇺🇸
PRA Health Sciences - Salt Lake, Salt Lake City, Utah, United States

A Single and Multiple Ascending Dose Study of BMS-986318 in Healthy Participants

Phase 1

Withdrawn

Conditions: Healthy Participants

Interventions: Drug: BMS-986318
Other: Placebo

First Posted Date: 2019-09-09

Last Posted Date: 2020-01-27

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT04082741

Locations: 🇺🇸
PRA Health Sciences - Lenexa, Lenexa, Kansas, United States

A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer

Phase 2

Completed

Conditions: Cancer
Breast Cancer

Interventions: Biological: Nivolumab
Drug: Anastrozole
Drug: Palbociclib

First Posted Date: 2019-09-03

Last Posted Date: 2022-08-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 23

Registration Number: NCT04075604

Locations: 🇺🇸
The Cancer Center At Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Hematology-Oncology Associates Of Fredricksburg, Inc, Fredericksburg, Virginia, United States
🇺🇸
MetroHealth Medical Center, Cleveland, Ohio, United States

and more 28 locations

A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327

Phase 1

Completed

Conditions: Healthy Participants
Idiopathic Pulmonary Fibrosis (IPF)

Interventions: Diagnostic Test: 18F-BMS-986327

First Posted Date: 2019-08-28

Last Posted Date: 2023-03-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 14

Registration Number: NCT04069143

Locations: 🇺🇸
Local Institution - 0001, New Haven, Connecticut, United States

A Study to Determine the Pharmacokinetic Profile of BMS-986165 Tablets

Phase 1

Completed

Conditions: Lupus

Interventions: Drug: BMS-986165-01
Drug: BMS-986165 Tablet
Drug: Famotidine

First Posted Date: 2019-08-22

Last Posted Date: 2021-01-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 33

Registration Number: NCT04065932

Locations: 🇬🇧
Quotient Sciences, Nottingham, United Kingdom

A Study to Investigate the Effects of Cytochrome P450 1A2 Induction by Ritonavir on BMS-986165 Drug Levels and Effects in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986165
Drug: Ritonavir

First Posted Date: 2019-08-13

Last Posted Date: 2020-06-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 16

Registration Number: NCT04055506

Locations: 🇺🇸
PRA Health Sciences - Salt Lake, Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy